Replies to post #63 on ISTA Pharmaceuticals Inc. (ISTA)

[surf1944]

7:30AM ISTA Pharm announces issuance of U.S. patent for Prolensa (ISTA) 8.38 : Co announced that the United States Patent and Trademark Office has issued Patent No. 8,129,431 with claims covering PROLENSA (bromfenac ophthalmic solution), ISTA's once-daily topical nonsteroidal anti-inflammatory product for the treatment of ocular inflammation and pain following cataract surgery. The patent was issued to ISTA's licensor, Senju Pharmaceuticals Co. Ltd., and was granted a patent term adjustment that extends the patent life originally set to expire January 2024 to September 2025.